In June 2012, pertuzumab (Perjeta), a new monoclonal antibody that binds and blocks the action of the HER2receptor in a manner complementary to that of trastuzumab, was approved for use in first-line metastatic HER2-positive breast cancer in combination with taxane chemotherapy and trastuzumab. Here, ERBB2 is linked to breast cancer.